The combination of immunotherapies and poly (ADP-ribose) polymerase inhibitors (PARPis) has been hypothesized to improve outcomes in advanced ovarian cancer (aOC). The FIRST/ENGOT-OV44 trial evaluated adding dostarlimab to first-line platinum-based chemotherapy (PBCT) and niraparib maintenance ± bevacizumab in patients with aOC.
Dostarlimab and niraparib in primary advanced ovarian cancer
Annals of Oncology | | A.-C. Hardy-Bessard, E. Pujade-Lauraine, R.G. Moore, F. Montestruc, A. Redondo, M.R. Mirza, D. Cibula, T.-E. Ciuleanu, L. Gilbert, R. Eitan, F. Zagouri, S. Pignata, R. Glasspool, J. Pfisterer, R. Phaëton, C.K. Anderson, M. Rodrigues, L. Gaba, E. Bakirtzi, J.M. Fauci, E. Kalbacher, F.B. Musa, S. Gorman, L.R. Duska, L. Gladieff, P. Braly, F. Joly, J. Thomes Pepin, I. Ray-Coquard, K.N. Moore
Topics: ovarian-cancer, chemotherapy